What about the risk of thrombosis with bioresorbable scaffolds?

Bioresorbable scaffolds promise to counteract late thrombosis by the absence of residual foreign material over time and the restoration of functional endothelial coverage. However, although currently available data are controversial, initial post-marketing studies have raised some concerns about the putative increased early thrombogenicity of bioresorbable scaffolds as compared to currently available second-generation drug-eluting stents. This article focuses on incidence rates, putative mechanisms and prevention strategies of scaffold thrombosis.